Amyotrophic Lateral Sclerosis Risk for Spinocerebellar Ataxia Type 2 ATXN2 CAG Repeat Alleles A Meta-analysis

被引:62
|
作者
Neuenschwander, Annalese G. [1 ]
Thai, Khanh K. [1 ]
Figueroa, Karla P. [1 ]
Pulst, Stefan M. [1 ]
机构
[1] Univ Utah, Dept Neurol, Salt Lake City, UT 84132 USA
关键词
POLYGLUTAMINE EXPANSIONS; ONSET; GENE; ALS; CLONING; AGE;
D O I
10.1001/jamaneurol.2014.2082
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
IMPORTANCE Repeats of CAG in the ataxin 2 gene (ATXN2) in the long-normal range (sometimes referred to as intermediate) have been identified as modifiers of amyotrophic lateral sclerosis (ALS) risk. Prior studies have used thresholding considering various cutoffs for ATXN2 repeat length. OBJECTIVE To calculate association between ATXN2 CAG repeat alleles and increased risk of ALS across multiple ethnic groups. DATA SOURCES The MEDLINE database was searched for studies published by December 29, 2013, reporting ATXN2 CAG repeat length in patients with ALS and controls. STUDY SELECTION Studies were included if they reported original data on relative risks or odds ratios (ORs) from ALS and control populations for individual ATXN2 alleles. Review articles that reported no new data were not included in the analysis. DATA EXTRACTION AND SYNTHESIS Analysis of allele distribution was performed to ensure that all studies followed identical allele sizing. The ORs, 95% confidence intervals, and population attributable risk percentages were calculated according to standard procedures. MAIN OUTCOMES AND MEASURES Occurrence of ALS associated with ATXN2 repeat alleles, expressed as ORs. RESULTS Nine studies were analyzed, including 7505 controls and 6151 sporadic ALS cases. The ALS and control cohorts were recruited from different geographical and ethnic regions including the United States, French Canada/Canada, Belgium and the Netherlands, Germany, Italy, mainland China, Turkey, and Flanders-Belgium. The ATXN2 CAG repeat lengths ranged from 13 to 39 in patients with ALS and from 13 to 34 in controls. The ORs were less than 1.00 for alleles with 25 to 28 repeats. The OR was 1.55 for 30 repeats, but this elevation was not statistically significant (95% CI, 0.88-2.73). The ORs were 2.70 (95% CI, 1.47-4.93) for 31 CAG repeats, 11.09 (95% CI, 4.16-29.57) for 32 repeats, and 5.76 (95% CI, 1.79-18.57) for 33 repeats. CONCLUSIONS AND RELEVANCE In contrast to prior studies with smaller numbers, risk for ALS associated with long-normal alleles is complex. Alleles with 27 and 28 repeats lower ALS risk slightly. The risk for ALS increases beginning with 29 repeats and reaches a maximum at 32 and 33 repeats. Of note, alleles with repeats of these lengths are known to be predisposed to meiotic expansion to full-penetrance mutant alleles. In patients with ALS, alleles with 31 to 33 repeats may have undergone preferential expansion in motor neurons during mitosis or DNA repair. Our meta-analysis provides a framework for counseling individuals with long-normal ATXN2 repeats.
引用
收藏
页码:1529 / 1534
页数:6
相关论文
共 50 条
  • [31] HTT, ATXN1 and ATXN2 CAG repeat size and risk for cancer and Parkinson disease.
    Perez Oliveira, Sergio
    Alvarez Fernandez, Ignacio
    Menendez-Gonzalez, Manuel
    David Duarte-Herrera, Israel
    Blazquez-Estrada, Marta
    Suarez, Esther
    Garcia-Fernandez, Ciara
    Siso-Garcia, Pablo
    Garcia-Gonzalez, Pablo
    Rosende-Roca, Maitee
    Boada, Merce
    Ruiz, Agustin
    Infante, Jon
    De la Casa Fages, Beatriz
    Gonzalez-Aramburu, Isabel
    Alvarez Martinez, Maria Victoria
    Pastor, Pau
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2024, 32 : 1474 - 1474
  • [32] Targeting ATXN2 Using Antisense Oligonucleotides as a Treatment for Spinocerebellar Ataxia Type 2 (SCA2)
    Scoles, Daniel
    Schneider, Matthew
    Meera, Pratap
    Figueroa, Karla
    Hung, Gene
    Rigo, Frank
    Bennett, Frank
    Otis, Thomas
    Pulst, Stefan
    NEUROLOGY, 2016, 86
  • [33] Intermediate CAG Repeat Expansion in the ATXN2 Gene Is a Unique Genetic Risk Factor for ALS-A Systematic Review and Meta-Analysis of Observational Studies
    Wang, Ming-Dong
    Gomes, James
    Cashman, Neil R.
    Little, Julian
    Krewski, Daniel
    PLOS ONE, 2014, 9 (08):
  • [34] CRISPR-Cas9 Gene Editing Strategies of ATXN2 for the Treatment of Spinocerebellar Ataxia Type 2
    Simpson, Bryan P.
    Keiser, Megan S.
    Monteys, Alex Mas
    Davidson, Beverly L.
    MOLECULAR THERAPY, 2019, 27 (04) : 112 - 112
  • [35] Spinocerebellar ataxia type 2 (SCA 2) in an infant with extreme CAG repeat expansion
    Babovic-Vuksanovic, D
    Snow, K
    Patterson, MC
    Michels, VV
    AMERICAN JOURNAL OF MEDICAL GENETICS, 1998, 79 (05): : 383 - 387
  • [36] Genetic Variance in the Spinocerebellar Ataxia Type 2 (ATXN2) Gene in Children with Severe Early Onset Obesity
    Figueroa, Karla P.
    Farooqi, Sadaf
    Harrup, Kristopher
    Frank, Johnathan
    O'Rahilly, Stephen
    Pulst, Stefan M.
    PLOS ONE, 2009, 4 (12):
  • [37] Clinical association between spinocerebellar ataxia type 2 and amyotrophic lateral sclerosis: A case report
    Aguilera-Rodriguez, R.
    Almaguer-Gotay, D.
    Almaguer-Mederos, L. E.
    Gonzalez-Zaldivar, Y.
    Estupinan-Rodriguez, A.
    Laguna-Salvia, L.
    Velazquez-Perez, L.
    Rodriguez-Pupo, J. M.
    MOVEMENT DISORDERS, 2013, 28 : S249 - S249
  • [38] Sex specific effect of ATXN2 rs7969300 polymorphism on age of onset in Spinocerebellar Ataxia type 2
    Almaguer-Mederos, Luis E.
    Gispert, Suzana
    Almaguer-Gotay, Dennis
    Aguilera-Rodriguez, Raul
    Gonzalez-Zaldivar, Yanetza
    Vazquez-Mojena, Yaime
    Cuello-Almarales, Dany
    Palenzuela, Daniel O.
    Auburger, Georg
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2022, 30 (SUPPL 1) : 260 - 261
  • [39] ATXN2 trinucleotide repeat length correlates with risk of ALS
    Sproviero, William
    Shatunov, Aleksey
    Stahl, Daniel
    Shoai, Maryam
    van Rheenen, Wouter
    Jones, Ashley R.
    Al-Sarraj, Safa
    Andersen, Peter M.
    Bonini, Nancy M.
    Conforti, Francesca L.
    Van Damme, Philip
    Daoud, Hussein
    Amador, Maria Del Mar
    Fogh, Isabella
    Forzan, Monica
    Gaastra, Ben
    Gellera, Cinzia
    Gitler, Aaron D.
    Hardy, John
    Fratta, Pietro
    La Bella, Vincenzo
    Le Ber, Isabelle
    Van Langenhove, Tim
    Lattante, Serena
    Lee, Yi-Chung
    Malaspina, Andrea
    Meininger, Vincent
    Millecamps, Stephanie
    Orrell, Richard
    Rademakers, Rosa
    Robberecht, Wim
    Rouleau, Guy
    Ross, Owen A.
    Salachas, Francois
    Sidle, Katie
    Smith, Bradley N.
    Soong, Bing-Wen
    Soraru, Gianni
    Stevanin, Giovanni
    Kabashi, Edor
    Troakes, Claire
    van Broeckhoven, Christine
    Veldink, Jan H.
    van den Berg, Leonard H.
    Shaw, Christopher E.
    Powell, John F.
    Al-Chalabi, Ammar
    NEUROBIOLOGY OF AGING, 2017, 51 : 178.e1 - 178.e9
  • [40] ATXN2 polyglutamine intermediate repeats length expansions in Malaysian patients with amyotrophic lateral sclerosis (ALS)
    Edgar, Suzanna
    Zulhairy-Liong, Nurul Angelyn
    Ellis, Melina
    Trivedi, Shuchi
    Zhu, Danqing
    Odongo, Jeffrey Ochieng
    Goh, Khean-Jin
    Capelle, David Paul
    Shahrizaila, Nortina
    Kennerson, Marina L.
    Ahmad-Annuar, Azlina
    NEUROGENETICS, 2025, 26 (01)